Globus Medical (NYSE: GMED) CFO corrects Form 4/A option data filing

Rhea-AI Filing Summary

Globus Medical Inc. senior vice president and CFO filed an amended insider trading report updating details of a prior stock option exercise and share sale. The amendment clarifies that on December 1, 2025, the officer exercised 4,896 stock options with an exercise price of $63.68 and then sold the underlying 4,896 shares of Class A common stock, rather than 5,000 options as previously reported.

The options relate to a grant made on January 27, 2022, which vests over four years, with one-fourth vesting on January 1, 2023 and the remainder vesting monthly over the following 36 months, and they expire on January 27, 2032. Following the corrected transaction, the officer beneficially owns 104 derivative securities (remaining options) directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kline Kyle

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
12/03/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$63.68	12/01/2025		M			4,896(1)	(2)	01/27/2032	Class A Common Stock	4,896	$0	104	D

Explanation of Responses:

1. On December 3, 2025, the reporting person filed a Form 4 which inadvertently reported in Table II that 5,000 options were exercised prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock that was reported in Table I. As correctly reported in this amendment, the reporting person exercised 4,896 options prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock.

2. These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Globus Medical (GMED) disclose in this amended Form 4/A?

The filing shows that the senior vice president and CFO corrected an earlier report to state that 4,896 stock options were exercised at $63.68 and the resulting 4,896 Class A shares were sold, instead of 5,000 options as originally reported.

Who is the insider involved in this Globus Medical (GMED) Form 4/A?

The insider is a senior vice president and chief financial officer of Globus Medical Inc., who filed the Form 4/A as a single reporting person with direct ownership of the reported securities.

How many Globus Medical (GMED) options were actually exercised and at what price?

The amendment states that the officer exercised 4,896 stock options with a $63.68 exercise price per option before selling the same number of underlying Class A common shares.

What error did the original Globus Medical (GMED) Form 4 make?

The original Form 4, filed on December 3, 2025, inadvertently reported in Table II that 5,000 options were exercised prior to the sale of 4,896 shares; the amendment corrects this to 4,896 options exercised.

What are the vesting terms of the corrected Globus Medical (GMED) stock options?

The options were granted on January 27, 2022 and vest over four years: one-fourth vests on January 1, 2023, and the remaining options vest ratably on a monthly basis over the next 36 months.

How many Globus Medical (GMED) derivative securities does the insider hold after this transaction?

After the reported transaction, the officer beneficially owns 104 derivative securities (remaining stock options) directly.